查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914647

生物製藥發酵系統市場－全球產業規模、佔有率、趨勢、機會及預測（依產品類型、應用、最終用戶、地區及競爭格局分類），2021-2031年

Biopharmaceutical Fermentation System Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type (Upstream Products, Downstream Products ), By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物製藥發酵系統市場預計將從 2025 年的 276.8 億美元成長到 2031 年的 455.9 億美元，複合年成長率達到 8.67%。

這些系統由專門的生物反應器和整合控制單元組成，旨在培養細菌和真菌等微生物，以大規模生產治療性蛋白質、疫苗和其他生物製藥。推動這一市場成長的關鍵因素包括：全球對生物製藥和生物相似藥的需求不斷成長、合約研發生產機構（CDMO）的能力迅速提升，以及需要生物療法的慢性疾病病例不斷增加。

市場概覽
預測期 2027-2031
市場規模：2025年 276.8億美元
市場規模：2031年 455.9億美元
複合年成長率：2026-2031年 8.67%
成長最快的細分市場 抗生素
最大的市場 北美洲

對藥物研發的大力財政支持進一步推動了該行業的擴張：歐洲製藥工業協會聯合會（EFPIA）報告稱，2024年，以研發為基礎的製藥業將在歐洲投入約550億歐元用於研發。儘管投資環境有利，但該市場仍面臨重大障礙：建造和維護符合嚴格監管標準的上游工程加工設施需要大量的資本投資和技術專長。

市場促進因素

全球慢性病發病率的上升推動了生物製藥研發管線的快速成長，這也是生物製藥發酵系統應用的主要促進因素。為了滿足單株抗體和重組蛋白日益成長的商業性需求，生產商正在對上游工程基礎設施進行大量投資，這需要建造配備先進生物反應器的大型設施。例如，諾和諾德在2024年6月發布的新聞稿《諾和諾德將在北卡羅來納州投資41億美元》中宣布，計劃新建一座生產建設計畫，以擴大其慢性病治療藥物的產能。

同時，製藥公司擴大將生產外包給合約研發生產機構（CDMO）以降低技術風險，從而推動了市場活躍度。 CDMO不斷升級其發酵生產線，並配備高密度生物反應器，以支援從疫苗到細胞療法等多元化的客戶組合。三星生物製劑於2024年10月發布的「2024年第三季財務業績」報告印證了這一趨勢，報告顯示，由於客戶需求成長，其合併累計銷售額達到3.2兆韓元。除了外包之外，成熟企業也正在擴大其內部生產能力。例如，賽諾菲於2024年5月宣布，將在維特里-蘇爾-塞納投資11億歐元新建一座生技生產設施，使其單株抗體產能翻倍。

市場挑戰

建立和維護符合規範的上游工程加工設施所需的大量資本投入和技術專長，是全球生物製藥發酵系統市場發展的一大阻礙因素。這種高進入門檻對中小型生物製藥公司的影響尤其顯著，這些公司往往缺乏足夠的財力來投資商業規模發酵所需的昂貴設備和複雜基礎設施。因此，這些系統的市場嚴重依賴大型製藥企業和合約研發生產機構（CDMO），這有效地限制了潛在基本客群，並減緩了系統的廣泛應用。

嚴峻的資金籌措環境進一步加劇了這種財務壓力，限制了這些資本密集型基礎設施計劃的可用流動性。當企業無法獲得足夠的資金籌措時，它們將被迫推遲或取消建造設施或升級設備的計劃。據英國生物產業協會稱，英國生技產業在2024年面臨嚴峻的公開市場環境，連續第二年沒有出現首次股票公開發行（IPO）。這種無法進入公開資本市場的局面直接阻礙了成長型企業籌集擴大生產基地所需資金的能力，使它們無法獲得發酵系統的新訂單。

市場趨勢

人工智慧 (AI) 和機器學習的融合正在改變全球生物製藥發酵系統市場，推動生產營運轉型為智慧化、數據驅動型製造。市場參與者正將 AI 演算法整合到生物反應器控制單元中，以實現預測性維護和即時代謝物監測，從而最大限度地減少批次失敗並提高滴度產量。安進公司在 2024 年 2 月發布的新聞稿中重點介紹了其“人工智慧賦能的俄亥俄州生物製造工廠”，凸顯了向數位化成熟基礎設施的轉變。該公司投資 3.65 億美元建造了該工廠，該工廠配備了先進的自動化系統，旨在最佳化生物製藥的生產可靠性。

同時，人們對永續和環境友善生物加工方法的日益關注，正促使發酵系統的設計和運作朝著嚴格的環境標準轉變。製造商們正積極尋求能夠減少碳排放和消費量的生物反應器解決方案和設施配置，市場也正朝著節能環保且相容可再生能源的技術方向發展。默克集團（Merck KGaA）於2024年1月宣布與華潤電力簽署長期綠色電力契約，凸顯了這一戰略轉變。該公司簽署了一份為期10年的協議，將供應300吉瓦時的再生能源，旨在實現其生產和供應鏈營運的脫碳。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球生物製藥發酵系統市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（上游工程產品（生物反應器/發酵槽、生物製程分析儀、製程監控系統等）、下游加工產品（過濾/分離、層析法、耗材、配件等））
    • 依應用領域（抗生素、重組蛋白等）
    • 依最終用戶（生物製藥產業、受託研究機構、學術研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章 北美生物製藥發酵系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲生物製藥發酵系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區生物製藥發酵系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物製藥發酵系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物製藥發酵系統市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球生物製藥發酵系統市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc
  • Lonza Group AG
  • Sartorius Stedim Biotech GmbH
  • Eppendorf SE
  • Danaher Corp
  • F Hoffmann-La Roche AG
  • Nova Biomedical Corp
  • Merck KGaA
  • Becton Dickinson & Co

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19551

The Global Biopharmaceutical Fermentation System Market is projected to expand from USD 27.68 Billion in 2025 to USD 45.59 Billion by 2031, achieving a CAGR of 8.67%. These systems consist of specialized bioreactors and integrated control units engineered to cultivate microorganisms, including bacteria and fungi, for the mass production of therapeutic proteins, vaccines, and other biological products. Key factors driving this market growth include the rising global demand for biologics and biosimilars, the rapid enhancement of capabilities within contract development and manufacturing organizations, and the increasing burden of chronic diseases that require biological treatments.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 27.68 Billion
Market Size 2031USD 45.59 Billion
CAGR 2026-20318.67%
Fastest Growing SegmentAntibiotics
Largest MarketNorth America

A strong financial dedication to drug development further reinforces the expansion of this sector. As reported by the European Federation of Pharmaceutical Industries and Associations, the research-based pharmaceutical industry allocated approximately €55,000 million to R&D across Europe in 2024. Despite this favorable investment atmosphere, the market encounters a major hurdle due to the significant capital expenditure and specialized technical expertise needed to construct and sustain upstream processing facilities that meet strict regulatory standards.

Market Driver

The swift growth of the biologics pipeline, spurred by the rising global incidence of chronic diseases, acts as a primary catalyst for the adoption of biopharmaceutical fermentation systems. Manufacturers are heavily investing in upstream processing infrastructure to satisfy the soaring commercial requirements for monoclonal antibodies and recombinant proteins, necessitating the construction of large-scale facilities equipped with advanced bioreactors. For instance, Novo Nordisk announced in a June 2024 press release titled 'Novo Nordisk to invest 4.1 billion USD in North Carolina' that it plans to build a new manufacturing plant to expand production capacity for its chronic disease therapies.

Concurrently, the increase in outsourcing to Contract Development and Manufacturing Organizations fuels market activity as pharmaceutical innovators seek to lower technical risks. CDMOs are continuously upgrading their fermentation lines with high-density bioreactors to handle diverse client portfolios ranging from vaccines to cell therapies. This trend is evident in Samsung Biologics' 'Third Quarter 2024 Financial Results' from October 2024, which reported a cumulative consolidated revenue of KRW 3.2 trillion due to rising client demand. Beyond outsourcing, established players are boosting internal capacities; for example, Sanofi committed €1.1 billion in May 2024 to create a new bioproduction site at Vitry-sur-Seine to double its monoclonal antibody production capacity.

Market Challenge

The significant capital expenditure and technical expertise required to establish and maintain regulatory-compliant upstream processing facilities serve as a major constraint on the Global Biopharmaceutical Fermentation System Market. This high barrier to entry disproportionately impacts small and medium-sized biopharmaceutical enterprises, which often lack the financial resilience to invest in costly capital equipment and the sophisticated infrastructure needed for commercial-scale fermentation. Consequently, the market for these systems relies heavily on large pharmaceutical corporations and Contract Development and Manufacturing Organizations, effectively limiting the potential customer base and slowing broader adoption.

This financial pressure is worsened by a tightening funding environment that restricts the liquidity available for such capital-intensive infrastructure projects. When companies are unable to secure sufficient backing, they are forced to delay or cancel plans for facility construction and equipment upgrades. According to the BioIndustry Association, the UK biotech sector faced a difficult public market environment in 2024, recording zero initial public offerings for the second consecutive year. This lack of access to public capital markets directly impedes the ability of growing companies to raise the necessary funds for expanding their manufacturing footprint, thereby hampering new orders for fermentation systems.

Market Trends

The integration of Artificial Intelligence and Machine Learning is transforming the Global Biopharmaceutical Fermentation System Market by shifting operations toward intelligent, data-driven manufacturing. Market players are embedding AI algorithms into bioreactor control units to facilitate predictive maintenance and real-time metabolite monitoring, thereby minimizing batch failures and maximizing titer yields. This move toward digitally mature infrastructure is exemplified by Amgen's February 2024 press release regarding its 'AI-enabled Ohio biomanufacturing facility,' where the company invested $365 million to establish a site featuring advanced automation designed to optimize biologic production reliability.

Simultaneously, the growing emphasis on sustainable and green bioprocessing practices is influencing the design and operation of fermentation systems to align with rigorous environmental standards. Manufacturers are actively pursuing bioreactor solutions and facility configurations that reduce carbon footprints and water consumption, pushing the market toward energy-efficient and renewable-compatible technologies. This strategic shift is highlighted by Merck KGaA's January 2024 announcement of a long-term green power agreement with China Resources Power, finalizing a ten-year contract for 300 gigawatt hours of renewable electricity to decarbonize its manufacturing and supply chain operations.

Key Market Players

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc
  • Lonza Group AG
  • Sartorius Stedim Biotech GmbH
  • Eppendorf SE
  • Danaher Corp
  • F Hoffmann-La Roche AG
  • Nova Biomedical Corp
  • Merck KGaA
  • Becton Dickinson & Co

Report Scope

In this report, the Global Biopharmaceutical Fermentation System Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biopharmaceutical Fermentation System Market, By Product Type

  • Upstream Products
    • (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others)
  • Downstream Products
    • (Filtration & Separation, Chromatography, Consumables, Accessories, Others)

Biopharmaceutical Fermentation System Market, By Application

  • Antibiotics
  • Recombinant Proteins
  • Others

Biopharmaceutical Fermentation System Market, By End User

  • Biopharmaceutical Industries
  • Contract Research Organization
  • Academic Research Institutes
  • Others

Biopharmaceutical Fermentation System Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biopharmaceutical Fermentation System Market.

Available Customizations:

Global Biopharmaceutical Fermentation System Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biopharmaceutical Fermentation System Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Upstream Products (Bioreactors/Fermentors, Bioprocess Analyzers, Process Monitoring System, Others), Downstream Products (Filtration & Separation, Chromatography, Consumables, Accessories, Others))
    • 5.2.2. By Application (Antibiotics, Recombinant Proteins, Others)
    • 5.2.3. By End User (Biopharmaceutical Industries, Contract Research Organization, Academic Research Institutes, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Biopharmaceutical Fermentation System Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biopharmaceutical Fermentation System Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Biopharmaceutical Fermentation System Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Biopharmaceutical Fermentation System Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Biopharmaceutical Fermentation System Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biopharmaceutical Fermentation System Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Biopharmaceutical Fermentation System Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Biopharmaceutical Fermentation System Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Biopharmaceutical Fermentation System Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Biopharmaceutical Fermentation System Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Biopharmaceutical Fermentation System Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biopharmaceutical Fermentation System Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Biopharmaceutical Fermentation System Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Biopharmaceutical Fermentation System Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Biopharmaceutical Fermentation System Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Biopharmaceutical Fermentation System Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Biopharmaceutical Fermentation System Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biopharmaceutical Fermentation System Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Biopharmaceutical Fermentation System Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Biopharmaceutical Fermentation System Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Biopharmaceutical Fermentation System Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biopharmaceutical Fermentation System Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Biopharmaceutical Fermentation System Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Biopharmaceutical Fermentation System Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biopharmaceutical Fermentation System Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc
  • 15.3. Lonza Group AG
  • 15.4. Sartorius Stedim Biotech GmbH
  • 15.5. Eppendorf SE
  • 15.6. Danaher Corp
  • 15.7. F Hoffmann-La Roche AG
  • 15.8. Nova Biomedical Corp
  • 15.9. Merck KGaA
  • 15.10. Becton Dickinson & Co

16. Strategic Recommendations

17. About Us & Disclaimer